122 related articles for article (PubMed ID: 31430659)
1. Extensive serum cytokine analysis in patients with prostate cancer.
Gong D; Wang Y; Wang Y; Chen X; Chen S; Wang R; Liu L; Duan C; Luo S
Cytokine; 2020 Jan; 125():154810. PubMed ID: 31430659
[TBL] [Abstract][Full Text] [Related]
2. Protein microarray analysis identifies key cytokines associated with malignant middle cerebral artery infarction.
Zhou Z; Zhang J; Li X; Xia C; Han Y; Chen H
Brain Behav; 2017 Aug; 7(8):e00746. PubMed ID: 28828208
[TBL] [Abstract][Full Text] [Related]
3. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Sardana G; Dowell B; Diamandis EP
Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
[TBL] [Abstract][Full Text] [Related]
4. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer.
Lynch DF; Hassen W; Clements MA; Schellhammer PF; Wright GL
Prostate; 1997 Aug; 32(3):214-20. PubMed ID: 9254901
[TBL] [Abstract][Full Text] [Related]
6. Extensive cytokine biomarker analysis in serum of Guillain-Barré syndrome patients.
Li X; Yang L; Wang G; Yuan Y; Wei N; Yang W; Wang X; Wang Z
Sci Rep; 2023 May; 13(1):8354. PubMed ID: 37221406
[TBL] [Abstract][Full Text] [Related]
7. Elevation of cytokine levels in cachectic patients with prostate carcinoma.
Pfitzenmaier J; Vessella R; Higano CS; Noteboom JL; Wallace D; Corey E
Cancer; 2003 Mar; 97(5):1211-6. PubMed ID: 12599227
[TBL] [Abstract][Full Text] [Related]
8. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
Meyer-Siegler KL; Bellino MA; Tannenbaum M
Cancer; 2002 Mar; 94(5):1449-56. PubMed ID: 11920501
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.
Gao CL; Rawal SK; Sun L; Ali A; Connelly RR; Bañez LL; Sesterhenn IA; McLeod DG; Moul JW; Srivastava S
Clin Cancer Res; 2003 Jul; 9(7):2545-50. PubMed ID: 12855629
[TBL] [Abstract][Full Text] [Related]
10. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array.
Zhang Y; Lin P; Hong C; Jiang Q; Xing Y; Tang X; Jiang H; Luo S; Chen X
Cytokine; 2018 Nov; 111():342-349. PubMed ID: 30273784
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity and binding kinetics of an ultra-sensitive chemiluminescent enzyme-linked immunosorbent assay at arrays of antibodies.
Tobos CI; Kim S; Rissin DM; Johnson JM; Douglas S; Yan S; Nie S; Rice B; Sung KJ; Sikes HD; Duffy DC
J Immunol Methods; 2019 Nov; 474():112643. PubMed ID: 31401067
[TBL] [Abstract][Full Text] [Related]
15. [Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy].
Cansino Alcaide JR; Vera San Martín R; Rodríguez de Bethencourt Codes F; Bouraoui Y; Rodríguez Berriguete G; Oueslati R; Pérez-Utrilla M; De la Peña Barthel J; Paniagua Gómez-Alvarez R; Royuela García M
Arch Esp Urol; 2009 Jun; 62(5):359-66. PubMed ID: 19721171
[TBL] [Abstract][Full Text] [Related]
16. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
17. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.
Veltri RW; Miller MC; Zhao G; Ng A; Marley GM; Wright GL; Vessella RL; Ralph D
Urology; 1999 Jan; 53(1):139-47. PubMed ID: 9886603
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic potential of serum proteomic patterns in prostate cancer.
Bañez LL; Prasanna P; Sun L; Ali A; Zou Z; Adam BL; McLeod DG; Moul JW; Srivastava S
J Urol; 2003 Aug; 170(2 Pt 1):442-6. PubMed ID: 12853795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
